Abbott
Also: ResApp announces results of prospective study on obstructive sleep apnea; Cosnumer telemedicine company Hims opens pharmacy operation in Columbus, Ohio.
Sanofi's deal with Abbott will be focusing on the diabetes space, while its deal with Happify will be looking at treating MS symptoms using a digital therapeutic.
The company's executives lauded the CGM system, which saw a 72.9% increase in organic sales during the last quarter, and hinted at implementations of the tech beyond diabetes alone.
Onduo, Livongo, Abbott and others also shared news at the show.
The FDA approval closes a gap with competitors Dexcom and Abbott, as well as setting the company up for entry into the Medicare market.
Abbott joins Dexcom, Glooko and Roche as a data-sharing partner for the as-yet-unlaunched device.
MobiHealthNews tracked investments, pilots, partnerships and app launches from major pharma companies during the quarter.
The clearance brings US readers a feature long available in Europe, and paves the way for data plays.
The new product adds night-time alarms, making the low-cost 14-day CGM more useful.
Realtime blood glucose information will allow Livongo's platform to deliver more insights, coaching to people with diabetes.